Skip to content

Clinical efficacy of transcranial alternating current stimulation to improve cognitive function in patients with PSCI

Clinical efficacy of transcranial alternating current stimulation to improve cognitive function in patients with PSCI

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095137
Enrollment
Unknown
Registered
2025-01-02
Start date
2024-04-22
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke cognitive impairment

Interventions

The Treatment Group:The intervention group underwent transcranial alternating current stimulation (tACS) stimulation, routine internal medical treatment, and conventional rehabilitation functional tra
The Control Group:The intervention group underwent sham stimulation, routine internal medical treatment, and conventional rehabilitation functional training.

Sponsors

The Affiliated Rehabilitation Hospital, Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age between 35 and 80 years old; 2. First occurrence of cerebral stroke (hemorrhagic/ ischemic) with a duration of 2 weeks to 6 months; 3. Diagnosis conforms to the diagnostic criteria of post-stroke cognitive impairment outlined in the "Expert Consensus on the Management of Post-Stroke Cognitive Impairment 2021"; 4. MoCA (Montreal Cognitive Assessment) scores: <=13 for illiterate individuals, <=19 for 1-6 years of education, <=24 for 7 years of education and above; 5. No metallic implants or pacemakers in the body; 6. Capable of understanding and cooperating with the rehabilitation assessment and treatment involved in this study; 7. Informed consent form to be signed by the patient or their immediate family member.

Exclusion criteria

Exclusion criteria: 1. Patients with cognitive impairment caused by other conditions such as brain tumors, senile dementia, hypothyroidism, or traumatic brain injury; 2. Individuals with residual effects from lacunar infarctions in the past; 3. Individuals or families with a history of epilepsy or mental illness; 4. Those with consciousness disorders, severe visual, auditory, or speech impairments; 5. Patients with fever, electrolyte imbalances, or unstable vital signs; 6. Individuals with severe dysfunction in vital organs such as heart, lungs, liver, or kidneys; 7. Patients with contraindications to tDCS, such as local skin injuries or inflammation, skull defects, or those with tactile hypersensitivity in the stimulation area.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment(MoCA);Trail Making Test A/B(TMT);

Secondary

MeasureTime frame
Digit Span Test;Rey-Osterrieth Complex Figure Test (ROCF);Resting-State Electroencephalography (EEG);The latency and amplitude of event-related potential P300;

Countries

China

Contacts

Public ContactKong Weicheng, Xue Xiehua

The Affiliated Rehabilitation Hospital, Fujian University of Traditional Chinese Medicine

kwcheng0806@163.com+86 178 5085 9802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026